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Background: Recent studies have shown that over 50% of people travelling to South East Asia 
return colonised with multidrug-resistant Enterobacterales (MRE) including carbapenemase-
producing Enterobacterales. Importation of MRE by travellers and subsequent spread to family 
members, communities, and healthcare facilities poses real risks that have not yet been 
adequately assessed. This systematic review and meta-analysis aims to quantify the risk factors 
and interventions for reducing the risk of MRE acquisition among international travellers.
Methods: A systematic search was conducted in PubMed, Web of Science, and Scopus for 
analytical epidemiological studies containing data post-2000 that assessed the risk factors to 
acquire and/or interventions to reduce the risk of MRE acquisition in travellers. Two 
researchers independently screened all the studies and extracted the information, and 
disagreements were resolved through consensus. The proportions of MRE acquisition by the 
region of destination and the odds ratio (OR) for the different risk factors and/or interventions 
were pooled using the inverse variance heterogeneity model. 
Results: Twenty studies (5253 travellers from high-income countries) were included in the 
meta-analysis. South Asia (58.7%, 95%CI:44.5-72.5%) and Northern Africa (43.9%; 
95%CI:37.6-50.3%) were the travel destinations with the highest proportion of MRE 
acquisition. Inflammatory bowel disease (OR 2.1; 95%CI:1.2-3.8), use of antibiotics (OR 2.4; 
95%CI:1.9-3.0), traveller’s diarrhoea (OR 1.7; 95%CI:1.3-2.3), and contact with the healthcare 
system overseas (OR 1.5; 95%CI:1.1-2.2) were associated with MRE colonisation. Vegetarians 
(OR 1.4; 95%CI:1.0-2.0) and backpackers (OR 1.5; 95%CI:1.2-1.8) were also at  increased 
odds of MRE colonisation. Few studies (n=6) investigated preventive measures and found that 
consuming only bottled water/beverages, meticulous hand hygiene, and probiotics had no 
protective effect on MRE colonisation.
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Conclusions: International travel is an important driver for MRE spread worldwide. Future 
research needs to identify effective interventions to reduce the risk of MRE acquisition as well 
as design strategies to reduce local transmission on return.
Registration: PROSPERO CRD42018076853.
Keywords: antibiotic; antimicrobial; resistance; transmission; carriage; meta-analysis
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There is a large clinical and public health burden associated with antimicrobial 
resistance (AMR) in bacteria causing human infections. This burden is increasing over time 
and urgent action is required.1,2 In a report commissioned by the UK Prime Minister, it was 
estimated that globally AMR could lead to 10 million excess deaths per year, and a cumulative 
cost of US$100 trillion by 2050.3 The problem of AMR is much more pronounced in low-
income countries with poor water quality and sanitation, uncontrolled use of antibiotics, 
inadequate infrastructure, and poor governance (i.e. corruption) all being important 
contributers.4,5
Although carriage of multidrug-resistant Enterobacterales (MRE) is much more 
prevalent in communities in low-income countries (mainly in South East Asia, Western Pacific, 
and Eastern Mediterranean regions),6 high-income countries are not immune to this problem7 
(particularly in hospitals and long-term care facilities where there is high prevalence of MRE), 
and multi-resistant bacteria may also spread from country to country.8 Global trade of food 
(including live animals) and international travel play major roles in the spread and transmission 
of resistant organisms.9 The number of persons crossing international borders has continued to 
increase over many decades, which has provided an important opportunity for dissemination 
of MRE to other countries. Asymptomatic carriers can transport MRE between countries in 
their gut at alarming rates e.g., studies have found that 89% of travellers returning from India 
and Sri Lanka to the United Kingdom were MRE carriers.10 These travellers, including medical 
tourists,11 can transmit organisms to household contacts,12,13 and may introduce the organism 
into the community,14 healthcare facilities,15 and the environment. Once established, these 
resistant organisms are extremely expensive and difficult to control.
In addition to the public health perspective of the risk of introduction of multidrug 
resistant pathogens, special clinical considerations should be taken with returning travellers 
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that are carriers of MRE. For example, studies have reported an association between 
international travel and extended-spectrum β-lactamase-producing (ESBL) E. coli bacteraemia 
post trans-rectal ultrasound guided prostate biopsy16,17 raising the question of the role of 
screening and antibiotic prophylaxis in this group of patients.
In 2015, Hassing et al. conducted a systematic review that compiled the evidence of 
MRE detection among international travellers.18 However, they did not quantitatively analyse 
the data. Additionally, since the publication of the systematic review, findings from the 
COMBAT study,13 the largest study on MRE in travellers with over 2000 participants have 
been published. In this systematic review and meta-analysis, we update the evidence by 
including the most recent studies and quantifying the risk factors for MRE colonisation among 
international travellers.
Methods
The protocol was prospectively registered in PROSPERO (CRD42018076853) and the 
findings of this systematic review and meta-analysis are presented according to PRISMA 
reporting guidelines.19 
Search strategy and selection criteria
The original search strategy was designed in PubMed and converted for use in Web of 
Science and Scopus. The search included all articles published from 2000 until February 2019, 
and the search was updated in July 2019. Search terms related to “travel”, 
“Enterobacteriaceae”, and “drug resistance” were included. To achieve a comprehensive 
evaluation of the published evidence, the systematic search was supplemented with a forwards 
and backwards citation search as well as retrieving the first 20 similar articles from PubMed 
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for each of the studies included from the initial search. In addition, all references from relevant 
previous systematic reviews were hand searched to identify possible missed studies.
Eligible studies were analytical epidemiological studies among international travellers 
that reported the rate or risk (and protective) factors (i.e. compared MRE carriers versus non-
carriers) for MRE acquisition (e.g. due to contaminated food), colonisation (e.g. due to an 
underlying condition such as inflammatory bowel disease), or selection (due to use of 
antibiotics) on return, where data were available in an extractable format. Among the risk 
factors of interest were demographic characteristics, travel characteristics, past medical history, 
medication use and medical problems while overseas, food exposure, and reason for travel. 
Potential protective factors included vaccines, probiotics, and hand hygiene. MRE included 
ESBL, AmpC β-lactamase, or carbapenemase-producing Enterobacterales. For a study to be 
included, it must have reported the country/region of travel and screened all participants on 
return for MRE and not just targeting symptomatic participants (e.g. with diarrhoea or fever on 
return). Given that the aim of the review was to describe the current situation of MRE among 
international travellers, only studies containing data post-2000 were included. 
Studies reporting MRE acquisition among military personnel, refugees and asylum 
seekers, adoptees, travellers seeking medical attention, international inpatient transfers, or 
during mass gatherings (e.g. Hajj, Olympic games) were not included as these travellers were 
considered at higher risk and not deemed representative of the average traveller. Exclusion 
criteria also included studies conducted on animals, in vitro studies, conference abstracts or 
proceedings, descriptive studies (e.g. case series), and ecological studies. No language 
restriction was imposed.
Study selection and data extraction
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Titles and abstracts of all papers were extracted and uploaded to the Rayyan platform 
(http://rayyan.qcri.org/)20 for screening. Two authors (LFK and JS) independently screened the 
titles and abstracts on the Rayyan platform. The same authors examined the full-text papers for 
eligibility in accordance with the review protocol. Any disagreements were resolved through 
consensus. 
Data from the included studies were extracted and summarised in a spreadsheet, the 
recorded fields included 1) first author and year of publication; 2) country and study setting; 3) 
study population characteristics (e.g. mean/median age, proportion of females, number of 
travellers); 4) travel characteristics (e.g. travel destination, duration of travel); 5) rate of MRE 
detection (i.e. number of travellers that tested positive for MRE on return among the number 
of travellers that tested negative for MRE before travel); 6) risk (and protective) factors for 
MRE acquisition, colonisation, or selection; and 7) MRE isolate characteristics (e.g. type of 
bacteria and resistance genes). Adjusted effect estimates and 95% confidence intervals of the 
risk factors were extracted. If adjusted effect estimates were not available, unadjusted estimates 
were extracted or computed based on the sample size and number of events (i.e. MRE post-
travel) in the exposed and unexposed groups.
Statistical analysis
Two effect measures of interest were examined, the proportion of MRE detected and 
the odds ratio (OR) for risk factors. Previous reviews18,21,22 have reported large heterogeneity 
in the proportion of detection across studies, suggesting the absence of a common worldwide 
effect estimate for the proportion of MRE detection. Countries were grouped into geographical 
regions (i.e. South Asia, Asia [excluding countries in South Asia], Northern Africa, Sub-
Saharan Africa, South and Central America, North America, Europe, and Oceania) as in a 
previous systematic review by Hassing et al.18 The detailed list of countries per region can be 
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found in the supplementary material (S1). A meta-regression was fitted to examine if region of 
destination was a predictor for the observed heterogeneity. It was found that region of 
destination was the best predictor (accounted for over 45% of the observed variance) of MRE 
detection. Therefore, the proportions of MRE detection were pooled by the region of 
destination using the inverse variance heterogeneity (IVhet) model.23 Adjusted and unadjusted 
(when adjusted were not available) estimates along with their 95% confidence intervals were 
pooled for the different risk factors using the IVhet model. The secondary objective of the 
systematic review was to describe the most common bacteria isolated from the travellers as 
well as report the distribution of resistance genes. Proportion meta-analysis using the IVhet 
model was applied to pool the data from the types of bacteria and resistance genes in travellers. 
Statistical heterogeneity was assessed using the I2. Publication bias was assessed using the Doi 
plot and LFK index.24 All the analyses were conducted in MetaXL version 5.3 (EpiGear Int 
Pty Ltd; Sunrise Beach; Australia; http://www.epigear.com).
Results
Studies identified
The search identified 725 publications, 177 articles remained after the title and abstract 
screening. Full-text review of 177 publications was conducted, and 28 met the eligibility 
criteria. It was noted that there was overlap in participants in five sets of publications. Four13,25-
27 and two28,29 publications used data from the COMBAT and VOYAG-R studies, respectively. 
Three publications30-32 reported results from a Finnish cohort of travellers, two publications33,34 
from a cohort of Australian healthcare volunteers, and two publications35,36 from a cohort of 
Dutch travellers. Therefore, 20 datasets (from 28 publications) with 5253 travellers were 
included in this meta-analysis (S2).
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Characteristics of the included studies
All the studies were conducted in Europe (The Netherlands,12,13,35,37,38 Sweden,39-42 
Switzerland,43,44 France,28,45 Germany,38,46 Finland,30 United Kingdom,10 and Denmark47) 
except for three that were conducted in Australia,33 Japan,48,49 and the USA.49 The median age 
of the participants ranged from 25 to 66 years. Overall more females (n=3028, 57.6%) were 
included in the studies. The sample size ranged from 18 to 1847 participants. The median 
duration of travel ranged from 7 to 45 days, with 75% of the studies having a median duration 
of travel between 14 and 21 days. Thirteen studies collected stool samples,10,13,28,30,35,38-
40,42,43,46,48,49 five studies used rectal swabs,12,33,41,44,45 and two studies use a combination of both 
types of samples.37,47 Collection of the post-travel sample was done within one month after 
return in 70% of the studies. The majority of studies (n=19, 95%) used selective media for 
MRE detection that were mainly followed by genotyping confirmation, while one study only 
used meta-genomic approach for MRE detection35 (Table 1). 
Quantitative analysis
Proportion of MRE detection by region of destination
Overall, there was a wide variability in the proportion of MRE detected, ranging from 
13% to 88% and considerable heterogeneity across studies was observed. Heterogeneity 
substantially decreased when estimates were pooled by regions. South Asia (58.7%, 95%CI 
44.5-72.5%), Northern Africa (43.9%; 95%CI 37.6-50.3%), and Asia (37.5%; 95%CI 23.6-
51.9%) were the travel destinations with the highest proportion of MRE detection. These 
regions were followed by Sub-Saharan Africa (21.8%; 95%CI 12.0-32.4%), South and Central 
America (18.3%; 95%CI 8.8-28.9%), and North America (16.9%; 95%CI 2.6-35%); while the 
lowest proportion of detection were observed in Europe (10.3%; 95%CI 5.5-16.1%) and 
Oceania (6.9%; 95%CI 0-21.1%) (Figure 1).
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MRE detection was not associated with sex, age, or duration of travel, but it was 
dependent on the travel destination. In terms of past medical history, it was found that 
inflammatory bowel disease (OR 2.1; 95%CI 1.2-3.8) was a significant risk factor for MRE 
colonisation. While overseas, use of antibiotics (OR 2.4; 95%CI 1.9-3.0) was the strongest risk 
factor; antimalarial prophylaxis (OR 1.0; 95%CI 0.8-1.4) was not associated with MRE 
colonisation, but it should be noted that commonly used antimalarial medications include 
doxycycline (a broad spectrum antibiotic) as well as other medications (e.g. mefloquine, 
atovaquone/proguanil, chloroquine) that would not be expected to have an effect on selection 
of AMR Enterobacterales. Other factors associated with MRE colonisation were experiencing 
traveller’s diarrhoea (OR 1.7; 95%CI 1.3-2.3) and having contact with the healthcare system 
either as inpatients or outpatients (OR 1.5; 95%CI 1.1-2.2). With regards to food exposure, 
having a vegetarian diet (OR 1.4; 95%CI 1.0-2.0) was found to increase the odds of acquiring 
MRE compared to other diets, and consuming only bottled water/beverages did not have an 
impact on MRE colonisation. Among the interventions that were examined for their potential 
impact in decreasing the risk of MRE colonisation, meticulous (as defined by primary study 
authors) hand hygiene and probiotics had no effect, while oral cholera vaccine (OR 1.6; 95%CI 
1.0-2.5) was found to increase the odds of MRE colonisation, possible due to confounding by 
indication (see discussion). Backpacker travellers had a 50% (OR 1.5; 95%CI 1.2-1.8) 
increased odds of acquiring MRE compared to other types of travellers (Table 2).
Aetiology and resistance genes
Of the 2276 MRE isolates, the vast majority were E. coli (92.0%; 95%CI 84.9-97.3%) 
followed by K. pneumoniae (5.9%; 95%CI 1.2-11.8%). The remaining 2% of isolates included 
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Citrobacter spp. (freundii and amalonaticus), Proteus spp. (vulgaris and mirabilis), 
Enterobacter cloacae, Enterococcus faecium), Acinetobacter baumannii, Morganella 
morganii, and a case of non-Typhi Salmonella enterica.
blaCTX-M (92.3%; 95%CI 44.6-100%) was the most frequent resistance gene found in 
the MRE isolates. CTX-M group 1 was the most common followed by CTX-M groups 9 and 
4. blaSHV and blaTEM were found in 3.0% (95%CI 0-2.0%) and 2.0% (95%CI 0-1.8%) of the 
isolates, respectively. Enterobacterales with carbapenem- (blaOXA28,37,45 and blaNDM28,44,45) and 
colistin- (mcr48) resistance genes were also isolated. Fifty isolates with carbapenem-resistant 
genes were identified mainly from travellers returning from Southeast Asia and the Indian 
subcontinent,28,37,44,45 while the three isolates with colistin-resistant genes were from travellers 
returning from Vietnam.48
Discussion
In this systematic review and meta-analysis, we compiled data from 20 different studies 
with over 5000 travellers to update the evidence on the proportion and risk factors for MRE 
detection in international travellers. The highest proportions of MRE detection were observed 
from travellers returning from South Asia, Northern Africa, Asia, Sub-Saharan Africa, and 
South and Central America; our findings correspond with the global epidemiology of AMR4 
and the ESBL producing Enterobacterales colonisation prevalence among healthy 
individuals.50 In a meta-analysis by Karanika et el., international travellers were found to be 
four times more likely to be colonised by ESBL producing Enterobacterales than non-
travellers.50 These findings highlight the importance of international travel to low- and middle-
income countries in the global spread of MRE.51,52 In recent years, dissemination of emerging 
pathogens such as NDM-1 carbapenem-resistant K. pneumoniae from India53 and mcr-1 
colistin-resistant E. coli from China54 were facilitated by international travel.55,56 Of concern is 
Page 11 of 29
Journal of Travel Medicine































































that our review revealed that carbapenem-28,37,44,45 and colistin48-resistant Enterobacterales are 
being detected in international travellers. Investment in infrastructure to provide access to clean 
water, and adequate sanitation and hygiene may reduce transmission in low- and middle-
income countries,4 and possibly reduce the global spread of AMR.
Contact with the healthcare system, traveller’s diarrhoea, and antibiotic use while 
travelling were strongly associated with MRE detection. The possibility that these factors are 
associated through reverse causality with MRE cannot be excluded (i.e. MRE infection leading 
to contact with the healthcare system, traveller’s diarrhoea, and/or use of antibiotics). Even in 
the event the observed associations are due to reverse causality, these factors are markers for 
MRE detection and can be used to identify travellers at higher risk of being colonised by MRE. 
Among the risk factors identified, one that travellers have control over is antibiotic 
consumption, thus during pre-travel consultations, healthcare professionals need to emphasise 
the use of antibiotics only when is required. 
Acute diarrhoea is the most common condition affecting travellers to South and Central 
Asia and the second most common among travellers worldwide.57 Therefore, priority areas of 
research have been identified to generate evidence-based recommendations for preventing 
traveller’s diarrhoea.58 In line with the research priority areas, inflammatory bowel disease, a 
vegetarian diet, and backpacking were identified as host risk factors for MRE detection. 
Although it was not possible to examine the exposure to different classes and doses of 
antibiotics in the current review, findings by Ruppe et al.28 indicate that use of different classes 
of antibiotics have distinct effects on the risk of MRE selection. They found that antibiotics 
used for malaria prophylaxis (i.e. doxycycline) did not to increase the risk of MRE selection 
(OR 0.9; 95%CI 0.6-1.6), while beta-lactams were associated with an increase in risk (OR 4.2; 
95%CI 1.5-12.1).28 
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Non-antibiotic approaches to prevent MRE colonisation were also examined. Findings 
from the current review align with a recent randomised controlled trial that found that 
Lactobacillus rhamnosus GG did not reduce MRE colonisation in travellers.59 The effect of 
oral cholera vaccine was also assessed, and paradoxically it was found that cholera vaccine was 
associated with an increase in the risk of MRE colonisation. Considering that the oral cholera 
vaccine provides some cross-protection against enterotoxigenic E. coli, one of the most 
common causes of traveller’s diarrhoea, this association may seem contradictory. The most 
likely explanation for the observation is that unadjusted estimates were analysed and the result 
is affected by confounding by indication, i.e. travellers going to regions with higher risk of 
MRE are more likely to receive oral cholera vaccine. In our previous study of MRE detection 
in Australian travellers, those travelling to the Indian subcontinent were more likely to receive 
oral cholera vaccine than travellers going to other destinations; when the analysis was adjusted 
for travel destination and traveller’s comorbidities, the point estimate indicated a protective 
effect of oral cholera vaccine against MRE colonisation.60 To prevent confounding by 
indication, randomised controlled trials are needed to provide robust evidence on the effect of 
potentially protective interventions. 
It is clear that international travellers are a high risk group; over 50% of travellers 
returning from South Asia are asymptomatic MRE carriers and there is increasing evidence of 
subsequent household transmission of MRE.12,13 Cases of ESBL-producing E. coli bacteraemia 
have been reported after prostate biopsies17 and international travel has been identified as the 
risk factor for fluoroquinolone-resistant and ESBL-producing E. coli infections.16,61 Therefore, 
the role of screening and contact precaution of returned travellers from clinical and public 
health perspectives need to be further examined.62 It is unfeasible to screen all returning 
travellers, but in a healthcare setting, it may be feasible to screen those who are planning to 
undergo higher risk medical procedures; although current evidence suggest that ESBL-
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producing E. coli is less likely to spread between patients in hospitals than other 
Enterobacterales species.63 Current studies on international patient transfers have shown that 
targeted screening programs of high-risk patients  may be a more cost-effective strategy than 
mass screening64 and contact precaution and environmental cleaning with chlorine-based 
disinfectant can prevent transmission.65 Given that prolonged MRE carriage is uncommon, 
most travellers (~90%) are culture-negative within 6 months,28,33,46 strategies should aim to 
reduce transmission and avoid elective surgical interventions within this period.
The findings of our systematic review and meta-analysis should be understood in light 
of some of the limitations. Estimates extracted and synthesized from observational studies 
included adjusted as well as unadjusted estimates, thus pooled estimates may be affected by 
confounding variables. This may be the case of potential protective interventions, where 
paradoxical findings were observed. To examine regional and within-country differences in 
MRE detection, as well as the risk of different antibiotic classes and doses, more granular data 
are required. Individual patient data meta-analysis may provide valuable information to answer 
these questions. The current review examined the risk factors relevant to average travellers 
from high-income countries, thus findings may not be applicable to special groups of travellers 
such as military personnel, refugees and asylum seekers, or hospital transfers as they may have 
different risk profiles. The median age of travellers in the included studies ranged from 25 to 
66 years, so findings may not be generalizable to children. Some studies collected post-travel 
samples between 3 and 12 months post travel, thus we cannot rule out the possibility that the 
participants became colonised after their return. 
In conclusion, international travel is an important driver for MRE spread worldwide. 
South Asia as a travel destination is a major risk factor for MRE acquisition. Additional risk 
factors for individuals to become colonised, include inflammatory bowel disease, use of 
antibiotics, traveller’s diarrhoea, contact with the healthcare system, having a vegetarian diet, 
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and backpacking. Future research needs to identify effective interventions to reduce the risk of 
MRE colonisation and design strategies to reduce local transmission on return, including 
transmission to household and community members, as well as wider dissemination into the 
environment and animal populations 
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Table 2. Risk factors for acquisition of multidrug-resistant Enterobacterales
OR (95% CI) I2 (%) Number of studies with 
adjusted estimates/ 
Total number of studies
Demographic
Sex (female) 0.91 (0.80-1.03) 0 2 / 14
Age (per 10 year increase) 1.01 (0.97-1.06) 0 2 / 5
Travel associated data
Duration of travel (per week increase) 1.02 (0.99-1.06) 0 1 / 5
Travel destination (reference Europe)* 1 NA 0 / 10
South Asia 1.52 (1.31-1.76) 0 / 19
Northern Africa 1.33 (1.25-1.43) 0 / 11
Asia 1.26 (1.17-1.35) 0 / 16
Sub-Saharan Africa 1.12 (0.99-1.28) 0 / 15
Americas 1.11 (1.02-1.20) 0 / 16
Past medical history
Inflammatory bowel disease 2.09 (1.16-3.77) 0 1 / 3
Chronic disease 1.01 (0.65-1.57) 57 2 / 5
Admitted to a hospital in the previous 3-6 months 1.79 (0.09-36.63) 68 1 / 2
Antibiotic use in the previous 3-12 months 1.00 (0.76-1.32) 12 3 / 4
Medical history while overseas
Antibiotic use 2.38 (1.88-3.00) 0 4 / 12
Anti-acid use 1.08 (0.59-1.97) 25 0 / 5
Antimalarial prophylaxis 1.04 (0.75-1.44) 10 0 / 3
Travellers’ diarrhoea 1.69 (1.25-2.30) 46 5 / 13
Contact with healthcare system 1.53 (1.09-2.15) 20 1 / 10
Food exposure
Vegetarian diet 1.41 (1.01-1.96) 0 0 / 5
Only consume bottled water/beverages 1.29 (0.50-3.34) 77 1 / 6
Protective factors
Oral cholera vaccine 1.61 (1.04-2.50) 0 0 / 2
Meticulous hand hygiene 1.10 (0.81-1.49) 0 1 / 4
Probiotics 1.06 (0.78-1.45) 0 0 / 2
Type of traveller
Backpackers 1.46 (1.20-1.78) 0 2 / 7
Holiday makers 0.99 (0.70-1.38) 0 0 / 4
Visiting friends and relatives 0.95 (0.55-1.63) 29 0 / 5
Business travellers 0.78 (0.46-1.30) 0 0 / 4
OR odds ratio; CI confidence interval; NA not applicable 
* OR obtained through meta-regression. Americas include North, Central, and South America. Oceania was excluded 
from the analysis because too few studies (3) reported data for this region.
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Figure 1. Proportion of acquisition of multidrug-resistant Enterobacterales by region of destination
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S1. Countries by region
South Asia: Afghanistan, Bangladesh, Bhutan, India, Iran, Maldives, Nepal, Pakistan, Sri 
Lanka. 
Asia (without South Asia): Armenia, Azerbaijan, Bahrain, Brunei, Cambodia, China, Cyprus, 
Georgia, Hong Kong, Indonesia, Iraq, Israel, Jordan, Japan, Kazakhstan, Kuwait, Kyrgyzstan, 
Laos, Lebanon, Mongolia, Malaysia, Myanmar, North Korea, Oman, Philippines, Qatar, Saudi 
Arabia, South Korea, Singapore, Palestine, Syria, Tajikistan, Thailand, Timor-Leste, Turkey, 
Turkmenistan, United Arab Emirates, Uzbekistan, Vietnam, Yemen.
Northern Africa: Algeria, Egypt, Libya, Morocco, Sudan, Tunisia, Western Sahara.
Sub-Saharan Africa: Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape 
Verde, Central African Republic, Chad, Comoros, Congo (Brazzaville), Côte d’Ivoire, 
Democratic Republic of the Congo, Djibouti, Equatorial Guinea, Eritrea, Ethiopia, Gabon, 
Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, 
Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Reunion, Rwanda, São Tomé 
and Príncipe, Senegal, Seychelles, Sierra Leone, Somalia, South Africa, Sudan, Swaziland, 
Tanzania, The Gambia, Togo, Uganda, Zambia, Zimbabwe.
South and Central America: Anguilla, Antigua and Barbuda, Argentina, Aruba, Bahamas, 
Barbados, Belize, Bolivia, Bonaire, Sint Eustatius and Saba, Brazil, British Virgin Islands, 
Cayman Islands, Chile, Colombia, Costa Rica, Cuba, Curacao, Dominica, Dominican 
Republic, Ecuador, El Salvador, Falkland Islands, French Guiana, Grenada, Guadeloupe, 
Guatemala, Guyana, Haiti, Honduras, Jamaica, Martinique, Mexico, Montserrat, Nicaragua, 
Panama, Paraguay, Peru, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Martin, Saint 
Vincent and the Grenadines, Saint-Barthelemy, Sint Maarten, Suriname, Trinidad and Tobago, 
Turks and Caicos Islands, US Virgin Islands, Uruguay, Venezuela.
North America: Bermuda, Canada, Greenland, Saint Pierre and Miquelon, United States.
Europe: Aland Islands, Albania, Andorra, Austria, Belarus, Belgium, Bosnia and 
Herzegovina, Bulgaria, Channel Islands, Croatia, Czech Republic, Denmark, Estonia, Faeroe 
Islands, Finland, the former Yugoslav Republic of Macedonia, France, Germany, Gibraltar, 
Greece, the Holy See, Hungary, Iceland, Ireland, Isle of Man, Italy, Latvia, Liechtenstein, 
Lithuania, Luxembourg, Malta, Monaco, Montenegro, Netherlands, Norway, Poland, Portugal, 
Moldova, Romania, Russia, San Marino, Serbia, Slovakia, Slovenia, Spain, Svalbard and Jan 
Mayen, Sweden, Switzerland, Ukraine, United Kingdom.
Oceania: American Samoa, Australia, Cook Islands, Fiji, French Polynesia, Guam, Kiribati, 
Marshall Islands, Micronesia, Nauru, New Caledonia, New Zealand, Niue, Norfolk Island, 
Northern Mariana Islands, Palau, Papua New Guinea, Pitcairn Islands, Samoa, Solomon 
Islands, Tokelau, Tonga, Tuvalu, Vanuatu, Wallis and Futuna. 
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S2. PRISMA flow diagram for the selection of studies
*28 studies comprising 20 datasets
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